AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 142 min read$BLTE

Lin Yu-Hsin sold $66K of BLTE

Lin Yu-Hsin (Chief Executive Officer) sold 365 shares of BELITE BIO, INC (BLTE) at an average of $180.35 ($180.00–$180.57) across 2 trades on 2026-08-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lin Yu-Hsin
Published Aug 14, 2026, 10:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 10:16 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BLTE
Neutral
medium confidence
Mentioned
$BLTE
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLTENeutralLow
01

Why it matters

The CEO’s open-market sale under a pre-arranged 10b5-1 plan is typically treated as lower-signal than discretionary selling, limiting fundamental impact.

02

Market read

Traders may note the insider sale for sentiment, but there is no new company-specific catalyst in the text.

03

What to watch

The article does not provide any new operational, financial, or regulatory developments, so the trading signal is mostly sentiment-based.

Relevance 2/10Novelty 3/10Timing: filed Aug 14, 2026 after Aug 12 sale

Background

The article is a SEC Form 4 insider transaction disclosure for Belite Bio, Inc.

Company-level read

Ticker impact

$BLTENeutralMedium confidence
Context

Belite Bio CEO Lin Yu-Hsin sold about $65.8K of BLTE shares via an open-market sale under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and the disclosed value is relatively small versus typical market caps.

Market effects

Sector

No clear sector read-through from a small, 10b5-1-linked insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity rather than bearish fundamentals.

Key entities

  • issuer
    BELITE BIO, INC

    Company whose CEO reported an open-market sale of shares on Form 4.

  • insider
    Lin Yu-Hsin

    Chief Executive Officer and director who sold shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BLTE insider trading history →

Related articles

SEP 4
$BLTEMedAI 8/10

Belite Bio (BLTE) Is Up 9.0% After FDA Grants Priority Review To Tinlarebant Stargardt NDA

Belite Bio (BLTE) shares rose 9.0% after the FDA granted priority review to its new drug application for tinlarebant, a treatment for Stargardt disease. The company expects a decision by February 12, 2027, and is preparing for commercial launch, targeting 53,000 patients. Phase III data showed a 35.7% reduction in lesion growth versus placebo. The company projects $563.2 million revenue and $318.3 million earnings by 2029, a 24% upside to its current price.

simplywall.st3 min
AUG 12
$BLTEMedAI 8/10

BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA

Belite Bio (BLTE) said the FDA accepted its tinlarebant NDA for Stargardt disease type I and granted priority review. A decision is expected Feb. 12, 2027. Priority review targets action in six months. The filing is based on Phase III DRAGON results showing a 35.7% reduction in atrophic lesion growth rate vs placebo. BLTE shares rose about 6.2% on Tuesday.

tradingview.com4 min
AUG 12
$BLTEMedAI 8/10

Belite Bio lands priority review for first Stargardt treatment

The FDA accepted and granted priority review to Belite Bio’s (Nasdaq: BLTE) New Drug Application for tinlarebant to treat Stargardt disease type 1. The Prescription Drug User Fee Act target action date is Feb. 12, 2027. The program previously received breakthrough therapy, fast track, and rare pediatric designations, and has orphan drug status in multiple regions.

thepharmaletter.com4 min
JUL 20
$BLTEMedAI 8/10

Why Is Belite Bio Stock Gaining Monday? - Belite Bio (NASDAQ:BLTE)

Belite Bio (NASDAQ:BLTE) reported additional secondary endpoint statistics from its Phase 3 DRAGON trial of tinlarebant for Stargardt disease type 1. The company said qAF stayed stable or fell about 2% at 25 months with tinlarebant versus about a 20% increase with placebo, and the trial previously met its primary endpoint, reducing retinal lesion growth by 35.7% versus placebo. BLTE shares rose about 3.11% to $154.74.

benzinga.com4 min